Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
HASBROUCK HEIGHTS, N.J., March 29, 2017 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) provided an update today on the Company's development activities for Fexapotide Triflutate, its new drug for prostate enlargement. The Company is very pleased with the progress it has made, which is in line with its previous timeline announcements. The Company now expects to submit its initial filing seeking approval for Fexapotide Triflutate in the next few weeks. Nymox intends to provide fuller details at the above time.
For more information please contact [email protected] or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2015, and its Quarterly Reports.
Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com
